| CAS NO: | 1135695-98-5 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 513.49 |
|---|---|
| Formula | C26H25F2N3O6 |
| CAS No. | 1135695-98-5 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (194.74 mM) |
| Water:<1 mg/mL (slightly soluble or insoluble) | |
| Ethanol: 100 mg/mL (194.74 mM) | |
| Synonyms | QVD-OPH; Q-VD-OPH; Quinoline-Val-Asp-Difluorophenoxymethylketone. quinoline-val-asp(OMe)-CH2-OPH. |
| Other info | Chemical Name: (3S)-5-(2,6-difluorophenoxy)-3-[[(2S)-3-methyl-2-(quinoline-2-carbonylamino)butanoyl]amino]-4-oxopentanoic acid InChi Key: OOBJCYKITXPCNS-REWPJTCUSA-N InChi Code: InChI=1S/C26H25F2N3O6/c1-14(2)23(31-25(35)19-11-10-15-6-3-4-9-18(15)29-19)26(36)30-20(12-22(33)34)21(32)13-37-24-16(27)7-5-8-17(24)28/h3-11,14,20,23H,12-13H2,1-2H3,(H,30,36)(H,31,35)(H,33,34)/t20-,23-/m0/s1 SMILES Code: O=C(O)C[C@H](NC([C@@H](NC(C1=NC2=CC=CC=C2C=C1)=O)C(C)C)=O)C(COC3=C(F)C=CC=C3F)=O |
| In Vitro | Q-VD-OPh (5-100 μM) potently inhibits Actinomycin D-induced DNA laddering and subsequent apoptosis with minimal toxicity in WEHI 231 cells. Q-VD-OPh prevents caspase mediated cleavage of PARP and activation of the major initiator and effector caspases. Q-VD-OPh protects cardiac myocytes from virus-induced apoptosis in vitro |
|---|---|
| In Vivo | Q-VD-OPh inhibited caspase-7 activation and limited the pathological changes of tau and caspase cleavage in chronic treatment of Alzheimer disease. |
| Animal model | TgCRND8 mice in 3 months-old |
| Formulation & Dosage | Intraperitoneally Injected with 10 mg/kg QVD-OPh at 3 times a week for 3 months |
| References | J Cell Biochem. 2011 Nov;112(11):3334-42; Int J Clin Exp Med. 2009 Nov 5;2(4):300-8. |
|
|
|
|
m.cnreagent.com
